The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry
Recruiting
The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report da... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/15/2017
Locations: The International FOP Association, Casselberry, Florida
Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Recruiting
This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/02/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Recruiting
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Gender:
ALL
Ages:
Between 2 weeks and 40 years
Trial Updated:
11/10/2016
Locations: Sacramento Pediatric Gastroenterology, Sacramento, California
Conditions: Primary Sclerosing Cholangitis, Biliary Atresia
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
Recruiting
This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral... Read More
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
10/05/2016
Locations: Stanford University, Palo Alto, California
Conditions: Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections, PANS, PANDAS
Web Based Investigation of Natural History of Keloid Disorder, an Online Survey
Recruiting
This trial intends to gather very basic clinical information about keloid, its patterns of presentation, family history, ethnic background and correlation with the type of keloid, as well as prior treatment results that patients have had received.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2016
Locations: Michael H. Tirgan, MD, New York, New York
Conditions: Keloid
Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease
Recruiting
To identify demographic, clinical, genetic, immunologic and/or microbial (i.e., fecal stream characterization) risk factors that influence the likelihood of development of the HAEC phenotype in children who carry the diagnosis of HD. The newly formed HAEC Collaborative Research Group (HCRG) will utilize the 4 participating centers in the current consortia and recruit additional centers to enroll children diagnosed with Hirschsprung disease. 1a: To recruit 200 patients with Hirschsprung disease... Read More
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
08/10/2016
Locations: Cedars-Sinai Medical Center 8723 Alden Drive, Suite 240, Los Angeles, California
Conditions: Hirschsprung Disease, Enterocolitis
IRIS Registry: Intelligent Research in Sight Registry
Recruiting
The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.The IRIS Registry will be a centralized system for ophthalmology practices to promote practice innovations and achieve clinical excellence.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/11/2016
Locations: American Academy of Opthalmology, San Francisco, California
Conditions: Eye Diseases
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Recruiting
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.
Gender:
MALE
Ages:
All
Trial Updated:
06/29/2016
Locations: Houston Methodist, Houston, Texas
Conditions: Prostatic Neoplasms
Creatine for Depressed Male and Female Methamphetamine Users
Recruiting
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
12/10/2015
Locations: Montana State University College of Nursing (Missoula campus), Missoula, Montana
Conditions: Depression, Anxiety, Methamphetamine Dependence
Alzheimer's Disease Core Center
Recruiting
The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for Alzheimer's disease through genetic screening. All participants are seen annually. Autopsies to establish diagnoses in patients with dementia, patient... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/10/2015
Locations: University of Arizona, University Medical Center, Tucson, Arizona
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Recruiting
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is then treated with ad hoc regimens or early phase therapies with little benefit to the patient. Metronomic therapy (MC), defined as lower dose continuous drug exposure, has been successfully tested in pediatric leukemias with excellent results in terms of improved outcome, toxicity profiles, and cost.... Read More
Gender:
ALL
Ages:
Between 12 months and 31 years
Trial Updated:
05/13/2015
Locations: Miller Children's and Women's Hospital Long Beach, Long Beach, California +1 locations
Conditions: Solid Tumor
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Recruiting
In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/24/2014
Locations: Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado +4 locations
Conditions: Breast Cancer